Stock listing
NASDAQ:BPMC Blueprint Medicines Corp Stock
Follow Blueprint Medicines Corp into a list and get an email when it puts out news.
Last close · NASDAQ:BPMC
$129.46 USD
Close on Jul 17, 2025 · No longer trades
- Lowest – highest close
- $13.34 – $129.46 USDSince Apr 30, 2015 · lowest Feb 8, 2016 · highest Jul 17, 2025
Delisted NASDAQ:BPMC no longer trades. Its last trading date is unknown. Company history and updates stay available on this page.
- Ticker
- NASDAQ:BPMC
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
Blueprint Medicines Corp on 6ix
- Calls
- 17 calls with a replay · 17 with a transcript · latest May 1, 2025
- Decks
- 50 decks · latest May 1, 2025
Events
| Call | When | Status |
|---|---|---|
| Blueprint Medicines (BPMC) Q1 2025 Earnings Call | Wed, Apr 30, 2025 · 10:00 PM ET | Replay |
| Blueprint Medicines (BPMC) Q4 2024 Earnings Call | Thu, Feb 13, 2025 · 8:00 AM ET | Replay |
| Blueprint Medicines (BPMC) Q3 2024 Earnings Call | Wed, Oct 30, 2024 · 8:00 AM ET | Replay |
| Blueprint Medicines (BPMC) Q2 2024 Earnings Call | Thu, Aug 01, 2024 · 8:00 AM ET | Replay |
| Blueprint Medicines (BPMC) Q1 2024 Earnings Call | Thu, May 02, 2024 · 8:00 AM ET | Replay |
| Blueprint Medicines (BPMC) Q4 2023 Earnings Call | Mon, Mar 04, 2024 · 9:10 AM ET | Replay |
| Blueprint Medicines (BPMC) Q3 2023 Earnings Call | Thu, Oct 26, 2023 · 8:00 AM ET | Replay |
| Blueprint Medicines (BPMC) Q2 2023 Earnings Call | Wed, Aug 02, 2023 · 8:00 AM ET | Replay |
| Blueprint Medicines (BPMC) Q1 2023 Earnings Call | Thu, May 04, 2023 · 8:00 AM ET | Replay |
| Blueprint Medicines (BPMC) Q4 2022 Earnings Call | Thu, Feb 16, 2023 · 8:00 AM ET | Replay |
All 17 calls
| Call | When | Status |
|---|---|---|
| Blueprint Medicines (BPMC) Q2 2022 Earnings Call | Tue, Aug 02, 2022 · 8:00 AM ET | Replay |
| Blueprint Medicines (BPMC) Q1 2022 Earnings Call | Tue, May 03, 2022 · 8:30 AM ET | Replay |
| Blueprint Medicines (BPMC) Q4 2021 Earnings Call | Wed, Feb 16, 2022 · 8:30 AM ET | Replay |
| Blueprint Medicines (BPMC) Q3 2021 Earnings Call | Thu, Oct 28, 2021 · 8:30 AM ET | Replay |
| Blueprint Medicines (BPMC) Q2 2021 Earnings Call | Tue, Aug 10, 2021 · 8:30 AM ET | Replay |
| Blueprint Medicines (BPMC) Q1 2021 Earnings Call | Thu, Apr 29, 2021 · 8:30 AM ET | Replay |
| Blueprint Medicines (BPMC) Q4 2020 Earnings Call | Wed, Feb 17, 2021 · 8:30 AM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q1 2025 Earnings Presentation | Earnings | 14 slides | May 1, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 12 slides | Feb 13, 2025 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 25 slides | Jan 13, 2025 |
| Technical Presentation (April 2024) | Technical | 19 slides | Apr 25, 2024 |
| J.P. Morgan Healthcare Conference 2024 | Conference | 25 slides | Jan 8, 2024 |
| AAAAI 2023 Annual Meeting | Conference | 35 slides | Feb 27, 2023 |
| FY2022 Earnings Presentation | Earnings | 13 slides | Feb 16, 2023 |
| J.P. Morgan Healthcare Conference 2023 | Conference | 28 slides | Jan 9, 2023 |
| Investor Day (November 2022) | Investor day | 113 slides | Nov 1, 2022 |
| Investor Presentation (September 2022) | Investor deck | 24 slides | Sep 7, 2022 |
All 50 decks
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Habib Joseph Dable Other companies: Tyra Biosciences, Inc. (Director · Since at least Apr 16, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Relay Therapeutics, Inc. (Director · Since at least Nov 4, 2025); Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); PepGen Inc. (Director · Since at least Sep 20, 2022); Jade Biosciences, Inc. (Director · Jul 10, 2023 – Jun 5, 2024 · Past); Albireo Pharma Inc (Director · Aug 8, 2022 – Mar 2, 2023 · Past); Acceleron Pharma Inc (CEO and President, Director · Jan 4, 2021 – Nov 19, 2021 · Past) | Director · Since at least Jun 23, 2022 |
| Mark Alan Goldberg Other companies: Audentes Therapeutics Inc (Director · Dec 11, 2017 – Jan 15, 2020 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 9, 2017 · Past); Crescent Biopharma, Inc. (Director · Jul 8, 2014 – May 1, 2024 · Past); Aceragen Inc. (Director · Jan 7, 2014 – Jun 23, 2022 · Past); ImmunoGen Inc (Director · Nov 8, 2011 – Feb 12, 2024 · Past); Synageva BioPharma Corp (EVP, Medical & Reg. Strategy · Nov 2, 2011 – Sep 19, 2014 · Past) | Director · Since at least Jun 25, 2015 |
| Daniella Beckman Other companies: Upstream Bio, Inc. (Member, Board of Directors · Since at least Oct 10, 2024); Tango Therapeutics, Inc. (Chief Financial Officer · Since at least Aug 10, 2021); Vor Biopharma Inc. (Chair of the Audit Committee · Since at least Feb 4, 2021); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Translate Bio Inc (Director · Jun 18, 2019 – Sep 14, 2021 · Past) | Director · Since at least Dec 8, 2021 |
| Alexis Borisy Other companies: Parabilis Medicines, Inc. (Lead Independent Director; Chairman, Nextech Invest; Chairman, Curie.Bio · Since at least Jun 9, 2026); Revolution Medicines, Inc. (Director · Since at least Jun 26, 2025); Relay Therapeutics, Inc. (Director · Since at least Jun 6, 2025); Tango Therapeutics, Inc. (Director · Since at least Jun 5, 2025) | Director · Since at least Jun 18, 2025 |
| Lonnel Coats Other companies: Mineralys Therapeutics, Inc. (Board Member · Since at least Oct 19, 2026); Relay Therapeutics, Inc. (Director · Since at least Nov 4, 2025); Verve Therapeutics Inc (Director · Since at least Aug 8, 2022); Lexicon Pharmaceuticals, Inc. (Chief Executive Officer, Director · Jul 7, 2014 – Feb 28, 2024 · Past) | Director · Since at least Feb 3, 2016 |
| Lynn Seely Other companies: AbCellera Biologics Inc. (Director · Since at least Jun 30, 2026); Lyell Immunopharma, Inc. (President and CEO, Director · Since at least Jun 16, 2021); Myovant Sciences Ltd (Principal Executive Officer, Director · Apr 5, 2019 – Apr 3, 2020 · Past) | Director · Since at least Jun 19, 2019 |
| Christina Rossi Other companies: CG Oncology, Inc. (Biopharmaceutical Executive & Board Member · Since at least Nov 24, 2025); Xilio Therapeutics, Inc. (Director · Since at least Oct 21, 2021) | Chief Operating Officer · Since at least Oct 29, 2018 |
| Kyle Kuvalanka Other companies: Aktis Oncology, Inc. (Chief Financial Officer · Since at least Jan 8, 2026); Syros Pharmaceuticals, Inc. (Chief Operating Officer · Jun 29, 2016 – Feb 10, 2017 · Past) | Chief Business Officer · Apr 30, 2015 – Apr 30, 2015 · Past |
| Becker Hewes Other companies: Damora Therapeutics, Inc. (Chief Medical Officer · Since at least Jan 5, 2026) | Chief Medical Officer · Since at least Jan 11, 2021 |
| Anthony L Boral | Chief Medical Officer · Nov 6, 2017 – Dec 14, 2020 · Past |
All 14 people
| Person | Seat |
|---|---|
| Ariel Hurley | Principal Accounting Officer · Since at least May 5, 2025 |
| Christopher K Murray | CHIEF TECHNICAL OPERATIONS · Oct 10, 2017 – Mar 7, 2024 · Past |
| Debra Durso-Bumpus | Chief People Officer · Since at least Aug 24, 2022 |
| Percy H Carter | Chief Scientific Officer · Since at least Jun 6, 2022 |
Log in to ask 6ix AI your own questions about Blueprint Medicines Corp.